Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma
(1) Background: Oesophageal cancers are often late-presenting and have a poor 5-year survival rate. The standard treatment of oesophageal adenocarcinomas involves neoadjuvant chemotherapy with or without radiotherapy followed by surgery. However, less than one third of patients respond to neoadjuvan...
Main Authors: | William Jiang, Jelske M. de Jong, Richard van Hillegersberg, Matthew Read |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/4/996 |
Similar Items
-
The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer
by: Cameron C. J. Lang, et al.
Published: (2022-02-01) -
Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients
by: Shereen El Mashed, et al.
Published: (2022-08-01) -
Peri-operative Chemotherapy in Patients with Oesophageal and Gastro-oesophageal Junction Cancer – Three Years of Experience
by: Z. Pechačová, et al.
Published: (2013-01-01) -
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
by: R. Mercieca-Bebber, et al.
Published: (2022-03-01) -
Epidemiology of Barrett’s oesophagus and oesophageal adenocarcinoma
by: Nancy Perez, et al.
Published: (2019-03-01)